- Home
- PMAX vs CNSP Comparison
PMAX vs CNSP Comparison
Compare PMAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMAX
- CNSP
- Stock Information
- Founded
- PMAX 2019
- CNSP 2017
- Country
- PMAX Hong Kong
- CNSP United States
- Employees
- PMAX N/A
- CNSP N/A
- Industry
- PMAX
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- PMAX
- CNSP Health Care
- Exchange
- PMAX Nasdaq
- CNSP Nasdaq
- Market Cap
- PMAX 6.5M
- CNSP 5.6M
- IPO Year
- PMAX 2024
- CNSP 2019
- Fundamental
- Price
- PMAX $0.38
- CNSP $0.84
- Analyst Decision
- PMAX
- CNSP Hold
- Analyst Count
- PMAX 0
- CNSP 1
- Target Price
- PMAX N/A
- CNSP N/A
- AVG Volume (30 Days)
- PMAX 730.6K
- CNSP 228.7K
- Earning Date
- PMAX 04-28-2025
- CNSP 08-13-2025
- Dividend Yield
- PMAX N/A
- CNSP N/A
- EPS Growth
- PMAX N/A
- CNSP N/A
- EPS
- PMAX N/A
- CNSP N/A
- Revenue
- PMAX $4,694,079.00
- CNSP N/A
- Revenue This Year
- PMAX N/A
- CNSP N/A
- Revenue Next Year
- PMAX N/A
- CNSP N/A
- P/E Ratio
- PMAX N/A
- CNSP N/A
- Revenue Growth
- PMAX N/A
- CNSP N/A
- 52 Week Low
- PMAX $0.28
- CNSP $0.73
- 52 Week High
- PMAX $4.70
- CNSP $148.00
- Technical
- Relative Strength Index (RSI)
- PMAX N/A
- CNSP 38.65
- Support Level
- PMAX N/A
- CNSP $0.73
- Resistance Level
- PMAX N/A
- CNSP $0.84
- Average True Range (ATR)
- PMAX 0.00
- CNSP 0.07
- MACD
- PMAX 0.00
- CNSP 0.00
- Stochastic Oscillator
- PMAX 0.00
- CNSP 31.47
About PMAX Powell Max Limited Class A Ordinary Shares
Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.